stockportfolio.pro
PODD vs TECH: Which Stock Is the Better Buy?
Insulet Corporation and Bio-Techne Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — PODD vs TECH, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Insulet Corporation (PODD) | Bio-Techne Corporation (TECH) | |
|---|---|---|
| Market cap | $11.4B | $11.0B |
| Revenue (latest FY) | $2.71B | $1.22B |
| Net income (latest FY) | $247.10M | $73.40M |
| Revenue growth (5y CAGR) | 24.5% | 10.5% |
| Net margin | 9.1% | 6.0% |
| Return on equity | 16.3% | 3.8% |
| P/E ratio | 38.4 | 101.2 |
| Dividend yield | — | 0.4% |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | Yes | Yes |
See the full PODD vs TECH breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open PODD's full financials → Open TECH's full financials →More comparisons
Frequently asked questions
Which is bigger, PODD or TECH?
Insulet Corporation is larger by market capitalization — $11.4B versus $11.0B.
Which grows faster, PODD or TECH?
Over the last five fiscal years, Insulet Corporation grew revenue faster — 24.5%/yr versus 10.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.